Rita C. Peters

Essential bio/pharma employees show hard work and dedication can pay off, for patients.

Shutting down the COVID-19 pandemic requires a global, selfless effort.

After a difficult year, biopharma science delivers promising results.

Resolving drug shortages starts with identifying the source of the problem.

Misleading messages contribute to eroding trust in public health agencies

Amid high expectations for a COVID-19 vaccine, biopharma readies production capacity, weighs external pressures.

Time sure flies, except when you are waiting for something to happen.

Data and science must guide FDA in making pressure-filled COVID-19 vaccine and therapy approval decisions.

Achieving herd immunity will require testing, data, a vaccine, and public support.

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?